On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna (NasdaqGS:MRNA) underwent significant index changes, adding to the Russell Midcap indices while exiting the Russell Top 200 indices. This reclassification might have signaled a shift in ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...